Brevan Howard Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Brevan Howard Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$333K	Buy	+2,180	New	+$265K	﹤0.01%	1649
2026 Q1	–	Sell	-5,740	Closed	-$585K	–	2574
2025 Q4	$585K	Buy	+5,740	New	+$490K	0.01%	1021

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Brevan Howard Capital Management's PVLA Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 2,180 shares worth $333K. The stake represents ﹤0.01% of the portfolio and ranks #1649 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in PVLA as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in PVLA in Q4 2025 and has held it in 2 quarters since. The position peaked at $585K in Q4 2025. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Brevan Howard Capital Management held 2,180 shares of Palvella Therapeutics worth $333K as of Q2 2026.
Palvella Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
Palvella Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1649 holding.
Brevan Howard Capital Management first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 2 quarters since.
Brevan Howard Capital Management's Palvella Therapeutics position peaked at $585K in Q4 2025.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.